AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Amylyx Pharmaceuticals, Inc.
Video analysis: AMLX
All videosNo video analysis for this stock yet. Request one from our team.
News: AMLX
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company's stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company's stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
20 stocks likely to lose money even if the bull market continues
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
Almitas Capital LLC Buys Shares of 974,881 Amylyx Pharmaceuticals, Inc. $AMLX
Almitas Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 974,881 shares of the company's stock, valued at approximately $17,509,000. Amylyx Pharmaceuticals comprises approximately 4.2% of Almitas
Deutsche Bank AG Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX
Deutsche Bank AG bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 557,937 shares of the company's stock, valued at approximately $10,021,000. Deutsche Bank AG owned 0.50% of Amylyx Pharmaceuticals at the end of the most
